Clinical trials: Arbovirus Infections
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01656174
- Testing
- Procleix Dengue Virus Assay
- Where
- 2 sites in United States
- Volunteers
- 35,035 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Yellow Fever, Rabies
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
- Trial name
- SAFYR (NCT06998004)
- Testing
- AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level
- Where
- 2 sites in Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Japanese Encephalitis
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged…
- Trial name
- NCT06372665
- Where
- China
- Volunteers
- 15,357 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis
Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation.
- Trial name
- NCT02933710
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chikungunya Virus
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
- Trial name
- NCT05072080
- Testing
- CHIKV VLP/adjuvant
- Where
- 47 sites in United States
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Dengue, Dengue Fever
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01943825
- Testing
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Venezuelan Equine Encephalitis
Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine
This study is being done to determine the safety and tolerability of a new investigational vaccine referred to as VEE IA/B V3526, which may induce production of specific antibodies in vaccinated humans, and may protect them…
- Trial name
- NCT00109304
- Testing
- VEE 3526
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Japanese Encephalitis
Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.
- Trial name
- NCT01559831
- Testing
- IXIARO
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study.
- Trial name
- NCT04786444
- Testing
- Biological Vaccine VLA1553
- Where
- 12 sites in United States
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
The study is designed as a Phase III, double-blind, multicenter, randomized, active-controlled, parallel-group design in which two groups of participants will receive either SII-YFV or STAMARIL® - a licensed and WHO pre-qualified…
- Trial name
- NCT05421611
- Testing
- STAMARIL, SII-YFV
- Where
- 2 sites in Kenya
- Volunteers
- 1,824 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Ross River Virus Disease (RRVD)
Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine
The primary objective of this study is to assess the safety and tolerability of the Ross River Virus (RRV) Vaccine in a healthy young adult population.
- Trial name
- NCT00717834
- Testing
- Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
- Where
- 10 sites in Austria, Belgium and 1 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Dengue, Dengue Hemorrhagic Fever
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2…
- Trial name
- NCT01411241
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Measles, mumps, and rubella vaccine
- Where
- 4 sites in Mexico
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Vaccines
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
The purpose of this study is to describe the burden of DENV illness among household members aged 6 months to 50 years of selected communities in Latin America and Southeast Asia.
- Trial name
- NCT02766088
- Testing
- Blood sample collection
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Healthy, Zika
GLS-5700 in Dengue Virus Seropositive Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02887482
- Testing
- GLS-5700
- Where
- 3 sites in Puerto Rico
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer